Jonsson N, Sjögren H O
J Exp Med. 1966 Mar 1;123(3):487-503. doi: 10.1084/jem.123.3.487.
Tests for transplantation immunity and for the occurrence of virus-neutralizing serum antibodies were performed on mice, inoculated when newborn with the Schmidt-Ruppin strain of Rous sarcoma virus (RSV-SR). Mice developing no palpable primary sarcomas showed a clear-cut resistance against the isografting of established specifically antigenic Rous tumors. Transplantation tests performed on primary tumor hosts after extirpation of the tumors revealed neither any clear-cut immunity nor tolerance to the specific transplantation antigen(s). Serial pretreatment of operated primary tumor animals with irradiated autologous or syngeneic tumor cells resulted in a clear-cut transplantation immunity. Virus-neutralizing activity was only found in a few sera from newborn infected mice, and in these cases there was no positive correlation with the transplantation immunity. It seems probable that a successful immunization against the RSV-SR specific transplantation antigen(s) prevents the development of primary tumors. There is no indication of any tolerance to this antigen in connection with the induction of primary tumors.
对新生时接种劳斯肉瘤病毒施密特-鲁平株（RSV-SR）的小鼠进行了移植免疫和病毒中和血清抗体出现情况的检测。未出现可触及原发性肉瘤的小鼠对已建立的特异性抗原性劳斯肿瘤的同基因移植表现出明显的抗性。在肿瘤切除后对原发性肿瘤宿主进行的移植试验既未显示出任何明显的免疫性，也未显示出对特异性移植抗原的耐受性。用经辐照的自体或同基因肿瘤细胞对手术切除原发性肿瘤的动物进行系列预处理，产生了明显的移植免疫。仅在少数新生感染小鼠的血清中发现了病毒中和活性，而且在这些情况下，其与移植免疫之间没有正相关关系。针对RSV-SR特异性移植抗原进行成功免疫似乎可预防原发性肿瘤的发生。没有迹象表明在原发性肿瘤诱导过程中对该抗原存在任何耐受性。
